Production (Stage)
Zentalis Pharmaceuticals, Inc.
ZNTL
$1.20
-$0.04-3.23%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -32.78% | 144.45% | -8.43% | 7.01% | -3.84% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -42.09% | 7.44% | -17.99% | 11.65% | 0.57% |
| Operating Income | -52.74% | 32.11% | 17.99% | -11.65% | 61.87% |
| Income Before Tax | -574.11% | 21.94% | 27.61% | 22.23% | 116.12% |
| Income Tax Expenses | -- | -51.85% | -187.10% | 143.97% | 32.41% |
| Earnings from Continuing Operations | -580.87% | 22.10% | 27.70% | 21.58% | 115.87% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -100.00% | -- | -- | -34.88% |
| Net Income | -579.53% | 22.07% | 27.68% | 21.55% | 115.93% |
| EBIT | -52.74% | 32.11% | 17.99% | -11.65% | 61.87% |
| EBITDA | -53.70% | 32.24% | 18.05% | -11.75% | 62.16% |
| EPS Basic | -574.37% | 22.55% | 28.19% | 32.87% | 113.31% |
| Normalized Basic EPS | -465.63% | -9.19% | 28.09% | 17.45% | 113.56% |
| EPS Diluted | -581.14% | 22.55% | 28.19% | 32.87% | 113.08% |
| Normalized Diluted EPS | -467.26% | -9.19% | 28.09% | 17.45% | 113.50% |
| Average Basic Shares Outstanding | 1.10% | 0.62% | 0.71% | 16.86% | 19.60% |
| Average Diluted Shares Outstanding | 0.68% | 0.62% | 0.71% | 16.86% | 20.10% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |